Advertisement

Uncommon Dementias

  • Camilla Ferrari
  • Benedetta Nacmias
  • Sandro Sorbi
Chapter

Abstract

Dementia is becoming a worldwide phenomenon. Alzheimer’s disease represents the first cause of cognitive impairment, followed by vascular and frontotemporal dementia. However, in addition to these well-studied causes, there is a large number of conditions that can cause dementia, such as infections, toxic–metabolic conditions, inflammatory–autoimmune disorders, or metabolic inborn errors. These uncommon causes of dementia, due to their heterogeneous clinical presentation, lack diagnostic criteria and occur rarely, are often misdiagnosed. Prevalence has been only partially estimated in young patients (age at onset <65 years), and management is based only on a few expert suggestions. However, correct diagnosis is of great importance, since some of these dementias are treatable and reversible.

This chapter presents a comprehensive summary of etiologies, clinical presentation, typical features, diagnostic strategies, and treatments of known, uncommon dementias.

Keywords

Uncommon dementia Young-onset dementia Neurodegenerative disease Reversible dementia 

References

  1. 1.
    Rossor MN, Fox NC, Mummery CJ, et al. The diagnosis of young-onset dementia. Lancet Neurol. 2010;9:793–806.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Harvey RJ, Skelton-Robinson M, Rossor MN, et al. The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry. 2003;74:1206–9.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Fujihara S, Brucki SM, Rocha MS, et al. Prevalence of presenile dementia in a tertiary outpatient clinic. Arq Neuropsiquiatr. 2004;62(3):592–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Panegyres PK, French K. Course and causes of suspected dementia in young adults: a longitudinal study. Am J Alzheimers Dis Other Demen. 2007;22(1):48–56.PubMedCrossRefGoogle Scholar
  5. 5.
    Shinagawa S, Ikeda M, Toyota Y, et al. Frequency and clinical characteristics of early-onset dementia in consecutive patients in a memory clinic. Dement Geriatr Cogn Disord. 2007;24(1):42–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Kelley BJ, Boeve BF, Josephs KA. Young-onset dementia: demographic and etiologic characteristics of 235 patients. Arch Neurol. 2008;65(11):1502–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Sampson EL, Warren JD, Rossor MN. Young onset dementia. Postgrad Med J. 2004;80:125–39.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Kuruppu DK, Matthews BR. Young-onset dementia. Semin Neurol. 2013;33:365–85.PubMedCrossRefGoogle Scholar
  9. 9.
    Sorbi S, Hort J, Erkinjuntti T, et al. EFNS-ENS guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol. 2012;19:1159–79.PubMedCrossRefGoogle Scholar
  10. 10.
    Roos RA. Huntington’s disease: a clinical review. Orphanet J Rare Dis. 2010;5:40–8.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Gallina P, Paganini M, Lombardini L, et al. Progress in restorative neurosurgery: human fetal striatal transplantation in Huntington’s disease. Review. J Neurosurg Sci. 2011;55(4):371–81.PubMedGoogle Scholar
  12. 12.
    Kumar A, Agarwal S, Agarwal D, et al. Myotonic dystrophy type 1 (DM1): a triplet repeat expansion disorder. Gene. 2013;522:226–30.PubMedCrossRefGoogle Scholar
  13. 13.
    Bruni AC, Takahashi-Fujigasaki J, Maltecca F, et al. Behavioral disorder, dementia, ataxia, and rigidity in a large family with TATA box-binding protein mutation. Arch Neurol. 2004;61(8):1314–20.PubMedGoogle Scholar
  14. 14.
    Murphy S, Gorman G, Beetz C, et al. Dementia in SPG4 hereditary spastic paraplegia: clinical, genetic, and neuropathologic evidence. Neurology. 2009;73(5):378–84.PubMedCrossRefGoogle Scholar
  15. 15.
    Bourgeois J, Coffey S, Rivera SM, et al. Fragile X premutation disorders – expanding the psychiatric perspective. J Clin Psychiatry. 2009;70(6):852–62.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Hagerman RJ, Hall DA, Coffey S, et al. Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems. Clin Interv Aging. 2008;3(2):251–62.PubMedCentralPubMedGoogle Scholar
  17. 17.
    Kaye EM. Update on genetic disorders affecting white matter. Pediatr Neurol. 2001;24:11–24.PubMedCrossRefGoogle Scholar
  18. 18.
    Köhler W. Leukodystrophies with late disease onset: an update. Curr Opin Neurol. 2010;23(3):234–41.PubMedCrossRefGoogle Scholar
  19. 19.
    Luda E, Barisone MG. Adult-onset adrenoleukodystrophy: a clinical and neuropsychological study. Neurol Sci. 2001;22:21–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Debs R, Froissart R, Aubourg P, et al. Krabbe disease in adults: phenotypic and genotypic update from a series of 11 cases and a review. J Inherit Metab Dis. 2013;36:859–68.PubMedCrossRefGoogle Scholar
  21. 21.
    Gieselmann V, Krägeloh-Mann I. Metachromatic leukodystrophy – an update. Neuropediatrics. 2010;41:1–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Fraidakis MJ. Psychiatric manifestations in cerebrotendinous xanthomatosis. Translational Psychiatry 2013:3,e302. doi: 10.1038/tp.2013.76.
  23. 23.
    Pareyson D, Fancellu R, Mariotti C, et al. Adult-onset alexander disease: a series of eleven unrelated cases with review of the literature. Brain. 2008;131:2321–31.Google Scholar
  24. 24.
    Klein CJ, Boes CJ, Chapin JE, et al. Adult polyglucosan body disease: case description of an expanding genetic and clinical syndrome. Muscle Nerve. 2004;29(2):323–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Labauge P, Horzinski L, Ayrignac X, et al. Natural history of adult-onset eIF2B-related disorders: a multi-centric survey of 16 cases. Brain. 2009;132:2161–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Bolsover FE, Murphy E, Cipolotti L, et al. Cognitive dysfunction and depression in Fabry disease: a systematic review. J Inherit Metab Dis. 2013. doi: 10.1007/s10545-013-9643-x
  27. 27.
    El Dib RP, Nascimento P, Pastores GM. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev. 2013;2:CD006663. doi: 10.1002/14651858.CD006663.pub3.
  28. 28.
    Guimarãesa J, Amaralb O, SáMiranda MC. Adult-onset neuronopathic form of Gaucher’s disease: a case report. Parkinsonism Relat Disord. 2003;9:261–4.CrossRefGoogle Scholar
  29. 29.
    Mistry PK, Cappellini MD, Lukina E, et al. A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol. 2011;86(1):110–5.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Beavan MS, Schapira AHV. Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Ann Med. 2013;45:511–21.PubMedCrossRefGoogle Scholar
  31. 31.
    Vanier MT. Niemann-Pick disease type C. Orphanet J Rare Dis. 2010;5:16.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Babacan-Yildiz G, Hanagasi H, Gurvit H, et al. A rare dementing disease: adult neuronal ceroid lipofuscinoses. J Neuropsychiatry Clin Neurosci. 2012;24(4):493–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Zini A, Cenacchi G, Nichelli P, et al. Early-onset dementia with prolonged occipital seizures: an atypical case of Kufs disease. Neurology. 2008;71(21):1709–12.PubMedCrossRefGoogle Scholar
  34. 34.
    Neudorfer O, Pastores GM, Zeng BJ, et al. Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients. Genet Med. 2005;7(2):119–23.PubMedCrossRefGoogle Scholar
  35. 35.
    Patterson MC. Gangliosidoses. Handb Clin Neurol. 2013;113:1707–8. doi: 10.1016/B978-0-444-59565-2.00039-3.PubMedCrossRefGoogle Scholar
  36. 36.
    Torres RJ, Puig JG, Jinnah HA. Update on the phenotypic spectrum of Lesch-Nyhan disease and its attenuated variants. Curr Rheumatol Rep. 2012;14:189–94.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9(7):689–701.PubMedCrossRefGoogle Scholar
  38. 38.
    Chouldhary S, Mcleod M, Torchia D, et al. Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL). J Clin Aesthet Dermatol. 2013;6(3):29–32.Google Scholar
  39. 39.
    Pescini F, Nannucci S, Bertaccini B, et al. The Cerebral Autosomal-Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) scale. A screening tool to select patients for NOTCH3 gene analysis. Stroke. 2012;43:2871–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Dichgans M, Markus HS, Salloway S, et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol. 2008;7:310–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Kaufman KR, Zuber N, Rueda-Lara MA, et al. MELAS with recurrent complex partial seizures, nonconvulsive status epilepticus, psychosis, and behavioral disturbances: case analysis with literature review. Epilepsy Behav. 2010;18(4):494–7.PubMedCrossRefGoogle Scholar
  42. 42.
    McFarland R, Taylor RT, Turnbull DM. A neurological perspective on mitochondrial disease. Lancet Neurol. 2010;9:829–40.PubMedCrossRefGoogle Scholar
  43. 43.
    Walterfanga M, Evansa A, Leong Looid JC, et al. The neuropsychiatry of neuroacanthocytosis syndrome. Neurosci Biobehav Rev. 2011;35:1275–83.CrossRefGoogle Scholar
  44. 44.
    Zeman A, Daniels G, Tilley L, et al. McLeod syndrome: life-long neuropsychiatric disorder due to a novel mutation of the XK gene. Psychiatr Genet. 2005;15(4):291–3.PubMedCrossRefGoogle Scholar
  45. 45.
    Hayflick J, Westaway SK, Levinson B, et al. Genetic, clinical, and radiographic delineation of Hallervorden–Spatz syndrome. N Engl J Med. 2003;348:33–40.PubMedCrossRefGoogle Scholar
  46. 46.
    Manyam BV. What is and what is not ‘Fahr’s disease’. Parkinsonism Relat Disord. 2005;11(2):73–80.PubMedCrossRefGoogle Scholar
  47. 47.
    Saleem S, Aslam HM, Anwar M. Fahr’s syndrome: literature review of current evidence. Orphanet J Rare Dis. 2013;8:156.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Taly AB, Meenakshi-Sundaram S, Sinha S, Swamy HS, Arunodaya GR. Wilson disease: description of 282 patients evaluated over 3 decades. Medicine (Baltimore). 2007;86(2):112–21.CrossRefGoogle Scholar
  49. 49.
    Aggarwal A, Bhatt M. Recovery from severe neurological Wilson’s disease with copper chelation. Int Rev Neurobiol. 2013;110:313–48.PubMedCrossRefGoogle Scholar
  50. 50.
    Paloneva J, Manninen T, Christman G, et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet. 2002;71:656–62.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Kaneko M, Sano K, Nakayama J, et al. Nasu-Hakola disease: the first case reported by Nasu and review. Neuropathology. 2010;30:463–70.Google Scholar
  52. 52.
    Guerreiro RJ, Lohmann E, Brás JM, et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia–like syndrome without bone involvement. JAMA Neurol. 2013;70(1):78–84.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Sikorska B, Knight R, Ironside JW, Liberski PP. Creutzfeldt-Jakob disease. Adv Exp Med Biol. 2012;724:76–90.PubMedCrossRefGoogle Scholar
  54. 54.
    Cali I, Castellani R, Yuan J, et al. Classification of sporadic Creutzfeldt–Jakob disease revisited. Brain. 2006;129:2266–77.PubMedCrossRefGoogle Scholar
  55. 55.
    Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt–Jakob disease. Brain. 2009;132:2659–68.PubMedCentralPubMedCrossRefGoogle Scholar
  56. 56.
    Rosenbloom MH, Atri A. The evaluation of rapidly progressive dementia. Neurologist. 2011;17(2):67–74.PubMedCentralPubMedCrossRefGoogle Scholar
  57. 57.
    Valcour V, Paul R, Chiao S, Wendelken LA, Miller B. Screening for cognitive impairment in human immunodeficiency virus. Clin Infect Dis. 2011;53(8):836–42.PubMedCentralPubMedCrossRefGoogle Scholar
  58. 58.
    Read PJ, Donovan B. Clinical aspects of adult syphilis. Intern Med J. 2012;42(6):614–20.PubMedCrossRefGoogle Scholar
  59. 59.
    Halperin JJ. Nervous system lyme disease: diagnosis and treatment. Curr Treat Options Neurol. 2013;15(4):454–64.PubMedCrossRefGoogle Scholar
  60. 60.
    Halperin JJ. Lyme disease: a multisystem infection that affects the nervous system. Continuum (Minneap Minn). 2012;18(6 Infectious Disease):1338–50.Google Scholar
  61. 61.
    Puéchal X. Whipple’s disease. Ann Rheum Dis. 2013;72(6):797–803.PubMedCrossRefGoogle Scholar
  62. 62.
    Graus F, Saiz A. Limbic encephalitis: an expanding concept. Neurology. 2008;70:500–1.PubMedCrossRefGoogle Scholar
  63. 63.
    Serratrice G, Pellissier JF, Serratrice J, De Paula A. Limbic encephalitis – evolving concepts. Bull Acad Natl Med. 2008;192(8):1531–41.PubMedGoogle Scholar
  64. 64.
    Mocellin R, Walterfang M. Velakoulis D Hashimoto’s encephalopathy: epidemiology, pathogenesis and management. CNS Drugs. 2007;21(10):799–811.PubMedCrossRefGoogle Scholar
  65. 65.
    Victor M. Alcoholic dementia. Can J Neurol Sci. 1994;21:88–99.PubMedGoogle Scholar
  66. 66.
    Chalouhi C, Faesch S, Anthoine-Milhomme MC, et al. Neurological consequences of vitamin B12 deficiency and its treatment. Pediatr Emerg Care. 2008;24(8):538–41.PubMedCrossRefGoogle Scholar
  67. 67.
    Ibrahim D, Froberg B, Wolf A, Rusyniak DE. Heavy metal poisoning: clinical presentations and pathophysiology. Clin Lab Med. 2006;26(1):67–97.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • Camilla Ferrari
    • 1
  • Benedetta Nacmias
    • 1
  • Sandro Sorbi
    • 1
  1. 1.Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA)University of FlorenceFlorenceItaly

Personalised recommendations